Gilead Stock News

Despite beating Street estimates on revenue and non-GAAP EPS, Gilead Sciences shares are down ~4% in after-hours trading.

Gilead Sciences, Inc. (NASDAQ:GILD) declares $0.73/share quarterly dividend, 2.8% increase from prior dividend of $0.71.Forward yield 4.26%

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2021. “Gilead is at an important p

Gileads (GILD) COVID-19 therapy remdesivir has claimed the top spot, overtaking AbbVies (ABBV) anti-inflammatory medication Humira in a list of drugs compiled by the

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q4 2021 Results - Earnings Call Transcript

Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

GlaxoSmithKline PLC announced a settlement worth $1.25 billion between its ViiV Healthcare and Gilead Sciences Inc on Tuesday in relation to patent violations by Gilead's Biktarvy, a medicine to treat

Gilead Sciences Inc. beat Wall Street's expectations for revenue in the fourth quarter, but the drug maker's earnings were hit by $2 billion in unexpected costs, most of it due to a legal settlement

Gilead Sciences Inc on Tuesday posted lower-than-expected fourth-quarter earnings, citing a $1.25 billion legal settlement involving HIV drug patents and a charge related to its collaboration with Arc

Futures Reverse Gains As Nail-biting Volatility Enters February World stocks began the new month on firmer ground, after a volatile January, as reassuring comments from Federal Reserve officials helped to calm rate-hike jitters even though US futures failed to extend recent gains. After closing out January with a furious two-day, dip-buying meltup thanks to a flood of inbound month-end rebalancing, US index futures briefly traded through Mondays highs, backed by decent rally in European equities where financials outperformed, boosted by solid UBS earnings, before dipping lower as the volatility seen in past days lingered. At 7:00am ET, emini S&P futures traded 0.23%, or 10.5 points lower, Nasdaq futures were also red, some 31 points or 0.15% lower, and Dow futures dropped 0.2% as investors weighed cautious rate-hike commentary from Fed officials and awaited earnings from firms including Alphabet and General Motors. Treasuries climbed and the dollar weakened. Oil fell, but held close to seven-year highs.

We've got a big day ahead with both economic prints and Q4 earnings reports.

Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.

Kite, a subsidiary of Gilead (GILD) announced that the FDA approved an update to the prescribing information of its CAR T-cell therapy Yescarta (axicabtagene ciloleucel), allowing the

Biotech's blue bloods are the best bets in the space right now.